A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 54-66

  Kargl, Julia ^a   Brown, Andrew J ^b   Andersen, Liisa ^a   Dorn, Georg ^a   Schicho, Rudolf ^a   Waldhoer, Maria ^a,c   Heinemann, Akos ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GLAXOSMITHKLINE   (United Kingdom)

^c HAGEDORN RESEARCH INSTITUTE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (3 HYDROXYPHENYL) 3 (4 METHYLPHENYL) 6 OXO 1H,4H,5H,6H PYRROLO[3,4 C]PYRAZOL 5 YL]BENZOIC ACID; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CID 16020046; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG ENDOTHELIUM; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SERUM RESPONSIVE ELEMENT; STABLE EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; WOUND HEALING; YEAST;

AZABICYCLO COMPOUNDS; BENZOATES; BLOOD PLATELETS; CALCIUM SIGNALING; CANNABINOID RECEPTOR ANTAGONISTS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HEK293 CELLS; HUMANS; LIGANDS; LYSOPHOSPHOLIPIDS; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PIPERAZINES; PLATELET AGGREGATION; PROTEIN TRANSPORT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SULFONES; WOUND HEALING;

EID: 84879314553     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204180     Document Type: Article

References (47)

1. Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, and Sánchez C (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:245-252.
2. Balenga NA, Aflaki E, Kargl J., Platzer W, Schröder R, Blättermann S, Kostenis E., Brown AJ, Heinemann A, and Waldhoer M (2011a) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21:1452-1469.
3. Balenga NA, Henstridge CM, Kargl J, and Waldhoer M (2011b) Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55. Adv Pharmacol 62:251-277.
4. Bowes J, Brown AJ, Hamon J, Jarolimek W., Sridhar A, Waldron G, and Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 11:909-922.
5. Brown AJ (2007) Novel cannabinoid receptors. Br J Pharmacol 152:567-575.
6. Brown AJ, Daniels DA, Kassim M, Brown S., Haslam CP, Terrell VR, Brown J, Nichols P.L., Staton PC, and Wise A, et al (2011) Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337:236-246.
7. Brown AJ, Goldsworthy SM, Barnes A.A., Eilert MM, Tcheang L, Daniels D, Muir A.I., Wigglesworth MJ, Kinghorn I, and Fraser NJ, et al (2003) The Orphan G proteincoupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312-11319.
8. Coma I, Clark L, Diez E., Harper G, Herranz J, Hofmann G., Lennon M, Richmond N, Valmaseda M., and Macarron R (2009) Process validation and screen re-producibility in high-throughput screening. J Biomol Screen 14:66-76.
9. Dowell SJ and Brown AJ (2002) Yeast assays for G-protein-coupled receptors. Receptors Channels 8:343-352.
10. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L., Simpson DG, Irving AJ, Rogers MJ, Rajnicek A.M., and Ross RA (2010) A role for L-alpha- lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160:762-771.
11. Heinemann A, Ofner M, Amann R., and Peskar BA (2003) A novel assay to measure the calcium flux in human basophils: effects of chemokines and nerve growth factor. Pharmacology 67:49-54.
12. Henstridge CM (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 89:179-187.
13. Henstridge CM, Balenga NA, Ford L.A., Ross RA, Waldhoer M, and Irving AJ (2009) The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23:183-193.
14. Henstridge CM, Balenga NA, Kargl J, Andradas C., Brown AJ, Irving A, Sanchez C, and Waldhoer M (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25:1835-1848.
15. Henstridge CM, Balenga NA, Schröder R, Kargl J.K., Platzer W., Martini L, Arthur S, Penman J., Whistler JL, and Kostenis E, et al (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604-614.
16. Heynen-Genel S., Dahl R, Shi S., Milan L, Hariharan S, Bravo Y., Sergienko E, Hedrick M, Dad S., and Stonich D, et al (2010a) Screening for Selective Ligands for GPR55. Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (U.S.), Bethesda, MD.
17. Heynen-Genel S., Dahl R, Shi S., Milan L, Hariharan S, Sergienko E., Hedrick M, Dad S, Stonich D., and Su Y, et al (2010b) Screening for Selective Ligands for GPR55. Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US), Bethesda, MD.
18. Huang L, Ramirez JC, Frampton G.A., Golden LE, Quinn MA, Pae HY, Horvat D, Liang L.J., and DeMorrow S (2011) Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91:1007-1017.
19. Kapur A, Zhao P, Sharir H., Bai Y, Caron MG, Barak L.S., and Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817-29827.
20. Kargl J, Balenga N, Parzmair G.P., Brown AJ, Heinemann A, and Waldhoer M (2012a) The cannabinoid receptor CB1 modulates the signaling properties of the lyso-phosphatidylinositol receptor GPR55. J Biol Chem 287:44234-44248.
21. Kargl J, Balenga NA, Platzer W, Martini L., Whistler JL, and Waldhoer M (2012b) The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55. Br J Pharmacol 165:2611-2619.
22. Kargl J, Haybaeck J, Stancic A., Andersen L, Marsche G, Heinemann A., and Schicho R (2013) O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med (Berl): 449-458.
23. Keese CR, Wegener J, Walker S.R., and Giaever I (2004) Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci USA 101:1554-1559.
24. Kotsikorou E, Madrigal KE, Hurst D.P., Sharir H., Lynch DL, Heynen-Genel S, Milan LB, Chung T.D., Seltzman HH, and Bai Y, et al (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50:5633-5647.
25. Lauckner JE, Jensen JB, Chen H.Y., Lu HC, Hille B, and Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704.
26. Mackie K and Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:E298-E306.
27. Oka S, Kimura S, Toshida T., Ota R, Yamashita A, and Sugiura T (2010) Lysophos-phatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147:671-678.
28. Oka S, Nakajima K, Yamashita A., Kishimoto S, and Sugiura T (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362:928-934.
29. Olesnicky NS, Brown AJ, Dowell S.J., and Casselton LA (1999) A constitutively active G-protein-coupled receptor causes mating self-compatibility in the mushroom Coprinus. EMBO J 18:2756-2763.
30. Perez-Gomez E., Andradas C, Flores J.M., Quintanilla M., Paramio JM, Guzman M, and Sanchez C (2012) The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene: 1-9.
31. 2. Pharmacol Rev 62:588-631.
32. Philipose S, Konya V, Sreckovic I., Marsche G, Lippe IT, Peskar B.A., Heinemann A., and Schuligoi R (2010) The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 30:2416-2423.
33. Pietr M, Kozela E, Levy R., Rimmerman N, Lin YH, Stella N, Vogel Z., and Juknat A (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett 583:2071-2076.
34. Piñeiro R., Maffucci T, and Falasca M (2011) The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30: 142-152.
35. Qin N, Neeper MP, Liu Y, Hutchinson T.L., Lubin ML, and Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231-6238.
36. Rowley JW, Oler AJ, Tolley N.D., Hunter BN, Low EN, Nix DA, Yost C.C., Zimmerman GA, and Weyrich AS (2011) Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 118:e101-e111.
37. Ryberg E, Larsson N, Sjögren S, Hjorth S., Hermansson NO, Leonova J, Elebring T, Nilsson K., Drmota T, and Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101.
38. Sawzdargo M, Nguyen T, Lee D.K., Lynch KR, Cheng R, Heng HH, George S.R., and O'Dowd BF (1999) Identification and cloning of three novel human G proteincoupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64:193-198.
39. Schröder R., Janssen N, Schmidt J., Kebig A, Merten N, Hennen S., Müller A, Blättermann S, Mohr-Andrä M, and Zahn S, et al. (2010) Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943-949.
40. Sedej M, Schröder R, Bell K., Platzer W, Vukoja A, Kostenis E., Heinemann A, and Waldhoer M (2012) D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells. J Allergy Clin Immunol 129:492-500, 500, e1-e9.
41. Sharir H and Abood ME (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126:301-313.
42. Staton PC, Hatcher JP, Walker D.J., Morrison AD, Shapland EM, Hughes JP, Chong E, Mander P.K., Green PJ, and Billinton A, et al (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139:225-236.
43. Waldeck-Weiermair M., Zoratti C, Osibow K., Balenga N, Goessnitzer E, Waldhoer M., Malli R, and Graier WF (2008) Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121:1704-1717.
44. Whyte LS, Ryberg E, Sims N.A., Ridge SA, Mackie K, Greasley PJ, Ross R.A., and Rogers MJ (2009) The putative cannabinoid receptor GPR55 affects osteo-clast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511-16516.
45. Yin H, Chu A, Li W., Wang B, Shelton F, Otero F., Nguyen DG, Caldwell JS, and Chen YA (2009) Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284:12328-12338.
46. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.
47. Zhang X, Maor Y, Wang J.F., Kunos G., and Groopman JE (2010) Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.